What are the ASCO recommendations for stage IV squamous cell carcinoma (SCC) non–small cell lung cancer (NSCLC)?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

For patients SCC, negative or unknown tumor EGFR-sensitizing mutation, ALK or ROS1 gene rearrangement status, and PS 0-1 (or possibly PS 2), the guidelines recommend the following:

  • If PDL-1 expression is high (TPS ≥50%), single-agent pembrolizumab should be used, if the patient has no contraindications to immune checkpoint therapy
  • Patients with low (TPS <50%) or unknown PDL-1 expression should be offered standard chemotherapy with a cisplatin- or carboplatin-based two-drug combination, unless they are not considered candidates for platinum-based therapy

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!